Connect with us

Hi, what are you looking for?



Johnson & Johnson Says Single Shot of Its Covid-19 Vaccine Neutralises Delta Variant

The data showed that the Johnson & Johnson single-shot COVID-19 vaccine-elicited neutralizing antibody activity against the Delta variant.

Covid-19 Vaccine being administered. (Source: Johnson & Johnson website)

New Brunswick: American multinational company Johnson & Johnson in an official statement said a single dose of its Covid-19 vaccine offers strong protection against the delta variant of the coronavirus, on Thursday. It added that the protection could last for at least eight months.

A Single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the statement read.

READ ALSO: Covid-19 Delta Variant Detected in 96 Countries, 11 More Than Last Week: WHO

“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, MD, PhD, Global Head, Janssen Research & Development, Johnson & Johnson.

The analysis was made after blood samples were obtained from the participants of the study. The data showed that the Johnson & Johnson single-shot COVID-19 vaccine-elicited neutralizing antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa where high efficacy against severe or critical disease was demonstrated.

READ ALSO: Covaxin Neutralises Alpha, Delta Covid-19 Variants Effectively: Top US Health Research Institute

The study also added that Johnson & Johnson’s single-dose COVID-19 vaccine was 85 percent effective against severe or critical disease. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta (P.2) variants during the study period.

According to the statement, J&J vaccine received Emergency Use Authorization (EUA) in the United States on February 27 and Conditional Marketing Authorization (CMA) by the European Commission on March 11, 2021.

The World Health Organization (WHO) gave Johnson & Johnson vaccine nod for Emergency Use Listing on March 12, 2021. The company is for regulatory approval in many more countries as well.

You May Also Like


SRINAGAR, Jammu and Kashmir – Sixty-year-old Dinesh Mondal and his ice cream cart have been a fixture on the streets of Srinagar for decades....


Recently, Welhungerhilfe and Concern worldwide, the two globally acknowledged organizations, released the Global Hunger Index (GHI)-2021. The report places India at 101st place amongst...


The Samyukta Kisan Morcha, an umbrella body of farmers' unions, said it will hold a peaceful nationwide rail roko protest from 10 am to...


New Delhi: The Central Board of Secondary Education (CBSE) on Monday night announced the dates for Class 10 and 12 term-1 board exams 2021-22....